Inventor
ELSON GREG
FR36 patents
⚠️ This page may combine multiple inventors who share the name “ELSON GREG”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
NOVIMMUNE SA
28 patentsUS7728114B2Jun 1, 2010
Anti-CD3 antibodies and methods of use thereof
NOVIMMUNE SA260 citations98
US8034344B2Oct 11, 2011
Anti-IL-6/IL-6R antibodies and methods of use thereof
NOVIMMUNE SA19 citations92
US7744884B2Jun 29, 2010
Neutralizing antibodies and methods of use thereof
NOVIMMUNE SA11 citations92
US7700098B2Apr 20, 2010
Anti-interferon gamma antibodies and methods of use thereof
NOVIMMUNE SA19 citations92
US7674884B2Mar 9, 2010
Neutralizing antibodies and methods of use thereof
NOVIMMUNE SA15 citations92
US7312320B2Dec 25, 2007
Neutralizing antibodies and methods of use thereof
NOVIMMUNE SA20 citations92
US9926382B2Mar 27, 2018
Methods for the generation of multispecific and multivalent antibodies
NOVIMMUNE SA16 citations90
US9688755B2Jun 27, 2017
Fc receptor-binding polypeptides with modified effector functions
NOVIMMUNE SA8 citations84
US9682142B2Jun 20, 2017
Anti-interferon gamma antibodies and methods of use thereof
NOVIMMUNE SA9 citations84
US10759862B2Sep 1, 2020
Anti-IL-6/IL-6R antibodies and methods of use thereof
NOVIMMUNE SA3 citations83
US9850304B2Dec 26, 2017
Anti-CD3 antibodies and methods of use thereof
NOVIMMUNE SA5 citations83
US9828430B2Nov 28, 2017
Anti-IL-6/IL-6R antibodies
NOVIMMUNE SA3 citations83
US9234034B2Jan 12, 2016
Methods of treating autoimmune diseases using anti-IL6/IL-6R complex antibodies
NOVIMMUNE SA4 citations83
US10047144B2Aug 14, 2018
Methods of purifying antibodies
NOVIMMUNE SA8 citations79
US10759858B2Sep 1, 2020
Anti-CD3 antibodies and methods of use thereof
NOVIMMUNE SA1 citations72
US10400044B2Sep 3, 2019
Anti-TLR4 antibodies and uses thereof
NOVIMMUNE SA1 citations72
US10597465B2Mar 24, 2020
Methods for the generation of multispecific and multivalent antibodies
NOVIMMUNE SA1 citations71
US10689441B2Jun 23, 2020
Anti—TLR4 antibodies and methods of use thereof
NOVIMMUNE SA4 citations68
US10556960B2Feb 11, 2020
Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkers
NOVIMMUNE SA2 citations68
US9688769B2Jun 27, 2017
Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkers
NOVIMMUNE SA2 citations66
US10023646B2Jul 17, 2018
Neutralizing antibodies and methods of use thereof
NOVIMMUNE SA1 citations63
US9540444B2Jan 10, 2017
Neutralizing antibodies and methods of use thereof
NOVIMMUNE SA1 citations63
US11613582B2Mar 28, 2023
Anti-IL-6/IL-6R antibodies and methods of use thereof
NOVIMMUNE SA0 citations62
US10982004B2Apr 20, 2021
Anti-TLR4 antibodies and uses thereof
NOVIMMUNE SA0 citations61
US9453076B2Sep 27, 2016
Anti-TLR4 antibodies and uses thereof
NOVIMMUNE SA1 citations61
US10844132B2Nov 24, 2020
Neutralizing antibodies and methods of use thereof
NOVIMMUNE SA0 citations52
US9534049B2Jan 3, 2017
Neutralizing antibodies and methods of use thereof
NOVIMMUNE SA0 citations52
US8029794B2Oct 4, 2011
Combining therapies targeting multiple toll-like receptors
NOVIMMUNE SA0 citations42
ELSON GREG
5 patentsUS8609822B2Dec 17, 2013
Neutralizing antibodies and methods of use thereof
ELSON GREG48 citations97
US8617880B2Dec 31, 2013
Chimeric toll-like receptor/MD-2 polypeptides and methods of use thereof
ELSON GREG1 citations62
US8546539B2Oct 1, 2013
Fc receptor-binding polypeptides with modified effector functions
ELSON GREG4 citations62
US8105595B2Jan 31, 2012
Methods of using neutralizing anti-TLR4/MD2 antibodies
ELSON GREG2 citations62
US8106018B2Jan 31, 2012
Chimeric toll-like receptor/MD-2 polypeptides and methods of use thereof
ELSON GREG1 citations62